Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Smoking, ACE-2 and COVID-19: ongoing controversies

Janice M. Leung, Don D. Sin
European Respiratory Journal 2020 56: 2001759; DOI: 10.1183/13993003.01759-2020
Janice M. Leung
Centre for Heart Lung Innovation and the Division of Respiratory Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Don D. Sin
Centre for Heart Lung Innovation and the Division of Respiratory Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Smoking increases severity of COVID-19 https://bit.ly/2yWp3jb

From the authors:

The three letters from D. Lutchman, K.D. McAlinden and co-workers, and K. Farsalinos and co-workers together capture the divergence in opinion on the impact of smoking on coronavirus disease 2019 (COVID-19) and whether the angiotensin-converting enzyme 2 (ACE-2) receptor mediates this relationship. At the heart of this controversy is whether smoking reduces or increases the risk of contracting COVID-19. K. Farsalinos and co-workers, through analysis of the pooled prevalence of current smoking across 11 case series determined that current smoking status was significantly lower than expected gender- and age-adjusted prevalence in COVID-19 patients. That smoking could potentially be protective against COVID-19 has not gone unnoticed by the public. Since late April, multiple media outlets have reported on this possibility, prompting the World Health Organization (WHO) to release a warning on 4 May, 2020, on tobacco use during this pandemic [1]. While we do not dispute that the prevalence of smoking in COVID-19 cases has been surprisingly low across the world, we would echo WHO's advice, based on emerging evidence that outcomes in COVID-19 are worse in patients who do smoke. An analysis conducted by Killerby et al. [2], of 220 hospitalised and 311 nonhospitalised patients with COVID-19 patients across six acute care hospitals and associated outpatient clinics in metropolitan Atlanta, Georgia, for instance, demonstrated that smoking was an independent risk factor for COVID-19 hospitalisation, carrying an odds ratio of 2.3 (95% CI 1.2–4.5). A recent meta-analysis has also shown that smokers have a relative risk of 1.34 (95% CI 1.07–1.67) of having more severe disease or experiencing refractory or progressive disease [3]. While smoking may not necessarily increase one's risk for contracting COVID-19, the biological and inflammatory cascade that occurs upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may be particularly devastating for a smoker.

K.D. McAlinden and co-workers raise the possibility that a similar effect could be occurring in patients who vape. Certainly, the risks of significant pulmonary injury with vaping are now well-described in the literature [4], and the multiple ways that vaping can cause cellular damage and impede the lung's response to infection are clearly delineated by the authors. The theoretical possibility that vaping could prime the lung for SARS-CoV-2 infection is still hypothetical, given that to date none of the epidemiological studies have reported on vaping prevalence amongst their COVID-19 patients. Several demographic factors, however, make such estimates unlikely to be obtained with much precision. For instance, consider the landscape of e-cigarette use in China, the first epicentre of COVID-19. A 2018 survey of 10 233 individuals in five Chinese cities found that only 0.9% had used e-cigarettes within the past 30 days [5]. Only 0.2% of those 65 years and older reported e-cigarette use within the past 30 days compared to 1.5% of those in the 15–24 year age range. Similarly, in 2016, of 32 931 adults included in the US National Health Interview Survey, 1.0% of those over 65 years reported current e-cigarette use compared to 4.6% of the 18–44 year age group [6]. Older age groups, the ones more likely to have severe COVID-19, present to a hospital, and therefore be captured by epidemiologists in their surveys, are therefore less likely to report current vaping. On the other hand, it may be difficult to ascertain the prevalence of vaping in younger age groups who are much more likely to vape, but also much more likely to have mild or asymptomatic COVID-19 infections that are not captured, either for their failure to present to a healthcare provider or the constraints placed on available tests in resource-limited settings. Nonetheless, we would argue for hospitals to capture these data as best they can and hope that data for mild cases in younger outpatients begin to be reported from around the world. Similar to smoking, it is possible that vaping may still be associated with worse outcomes, if not necessarily being a risk factor for contracting infection in the first place.

Finally, as D. Lutchman notes, if the culprit player for worse outcomes in smokers in this pandemic is the heightened ACE-2 receptor in the airway epithelium, soluble ACE-2 might be a therapeutic option. Indeed, we would agree with the excitement for this approach as this was the subject of a recent study by Monteil et al. [7], which showed that human recombinant soluble ACE-2 (hrsACE-2) reduced SARS-CoV-2 viral loads in infected Vero-E6 cells by a factor of 1000–5000. hrsACE-2 also inhibited SARS-CoV-2 infections of kidney and vascular organoids. hrsACE-2 is now under phase 2 investigation in Europe as a therapeutic agent for COVID-19 (ClinicalTrials.gov: NCT04335136). Whether such a therapy will be helpful for the smokers and patients with COPD who display higher levels of ACE-2 in their airways and may suffer worse outcomes from COVID-19 remains to be determined.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-01759-2020.Shareable

Footnotes

  • Conflict of interest: J.M. Leung has nothing to disclose.

  • Conflict of interest: D.D. Sin reports grants from Merck, personal fees for advisory board work from Sanofi-Aventis and Regeneron, grants and personal fees for research from Boehringer Ingelheim, grants and personal fees for lectures and advisory board work from AstraZeneca, personal fees for lectures and advisory board work from Novartis, outside the submitted work.

  • Received May 13, 2020.
  • Accepted May 13, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    World Health Organization. Tobacco Users May Be at an Increased Risk of #COVID19, both in Contracting the Disease and Complications. https://twitter.com/WHO_Europe/status/1257255102634745857 Date last accessed: 10 May 2020.
  2. ↵
    1. Killerby ME,
    2. Link-Gelles R,
    3. Haight SC, et al.
    Characteristics associated with hospitalization among patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 790–794. http://dx.doi.org/10.15585/mmwr.mm6925e1
    OpenUrl
  3. ↵
    1. Karanasos A,
    2. Aznaouridis K,
    3. Latsios G, et al.
    Impact of smoking status on disease severity and mortality of hospitalized patients with COVID-19 infection: a systematic review and meta-analysis. Nicotine Tob Res 2020; in press [https://doi.org/10.1093/ntr/ntaa107].doi:10.1371/journal.pone.0233147
  4. ↵
    1. Werner AK,
    2. Koumans EH,
    3. Chatham-Stephens K, et al.
    Hospitalizations and deaths associated with EVALI. N Engl J Med 2020; 382: 1589–1598. doi:10.1056/NEJMoa1915314
    OpenUrl
  5. ↵
    1. Huang J,
    2. Duan Z,
    3. Wang Y, et al.
    Use of electronic nicotine delivery systems (ENDS) in China: evidence from citywide representative surveys from five Chinese cities in 2018. Int J Environ Res Public Health 2020; 17: E2541. doi:10.3390/ijerph17072541
    OpenUrl
  6. ↵
    1. Bao W,
    2. Xu G,
    3. Lu J, et al.
    Changes in electronic cigarette use among adults in the United States, 2014–2016. JAMA 2018; 319: 2039–2041. doi:10.1001/jama.2018.4658
    OpenUrlCrossRef
  7. ↵
    1. Monteil V,
    2. Kwon H,
    3. Prado P, et al.
    Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020; 181: 905–913. doi:10.1016/j.cell.2020.04.004
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 56 Issue 1 Table of Contents
European Respiratory Journal: 56 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Smoking, ACE-2 and COVID-19: ongoing controversies
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Smoking, ACE-2 and COVID-19: ongoing controversies
Janice M. Leung, Don D. Sin
European Respiratory Journal Jul 2020, 56 (1) 2001759; DOI: 10.1183/13993003.01759-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Smoking, ACE-2 and COVID-19: ongoing controversies
Janice M. Leung, Don D. Sin
European Respiratory Journal Jul 2020, 56 (1) 2001759; DOI: 10.1183/13993003.01759-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Correspondence

  • Clinical outcomes of bronchiectasis in India
  • Reply: Clinical outcomes of bronchiectasis in India
  • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society